Some items had notable criterion failures: fit residuals outside +/−2.5; high chi-squared values with significant p-value, and significantly under- or over-discriminating item characteristic curves (Table 3).
Notable exclusion criteria include: age>65 years, poor quality mRNA, and significant structural brain pathology on post-mortem examination.
Notable exclusion criteria included history of cardiovascular disease, uncontrolled hypertension, eGFR of less than 55 mL/min/1.73 m (or <60 mL/min/1.73 m based on study center metformin labeling), or serum creatinine greater than 124 μmol/L for men and greater than 115 μmol/L for women.
Notable study exclusion criteria included: Bipolar Disorder (BP-I/II or NOS), a history of psychosis, current (<6 months) drug/alcohol abuse or dependence, history of seizures or known increased seizure risk, and any unstable medical condition.
Notable proposals of such criteria were stated in terms of sparse coding in [6], already discussed in [3], and more recently in [7], or in terms of Bayesian learning [8].
Nevertheless, they identified relatively few genes that met their criteria of notable outliers in the proteome/transcriptome comparisons.
Pathway analysis, using genes selected on the basis of relaxed criteria, revealed notable differences between these two traits.
It is notable that the Venice criteria include, under "replication C," also the possibility of "no association and failed replication," based on traditional nonsignificant results for the meta-analysis.
Unfortunately, in the guidance there are notable gaps in setting criteria for initiating close observation of study subjects with pre-existing liver diseases marked by high baseline AT measures.
The scores for both products generally indicated varying levels of satisfaction (as opposed to dissatisfaction, ie, mean scores were >3) for most criteria, with notable exceptions for AC only, being "ease of application" (score 2.60), "absorption into the skin" (score 2.15), and "consistency" (score 2.95).
